[From control of impaired carbohydrate tolerance to primary prevention of atherosclerosis. Encouraging results of the STOP-NIDDM trial].
Aronov
D M
DM
Research Center for Preventive Medicine, Moscow, Russia.
Bubnova
M G
MG
D020909:Acarbose / Q000627:therapeutic use*; D050260:Carbohydrate Metabolism; D003324:Coronary Artery Disease / Q000378:metabolism* / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D018149:Glucose Intolerance; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007004:Hypoglycemic Agents; D020909:Acarbose